Authors
Loading...
Randomized trial evaluates cognitive performance improvement in migraine patients receiving anti-CGRP or botulinum toxin, indicating potential cognitive benefits of effective treatment.
Martins et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: